I don't manufacture antibodies, and I honestly only have a loose understanding of the process. If I really like you, or your project I've got a 7 minute gradient, really expensive Thermo column and even more expensive high temperature heater necessary to make the column work properly to knock out standards that look like this
...and data from your mAB that look more like this ...
Which is clearly your protein, cause my standard looks a great. It isn't that it was selected from a broad range of possible proteins to find the one that was absolutely the most amenable to mass spectrometry, or at a level of clean that is completely impossible in a production environment.
I know that CHO cells (Canadian Hippo Organoid - name suggested by a 4 year old, it actually might be something that sounds far more disturbing) cells are often used for production.
Want to know more about the process? Check out this new paper!
It turns out that there are multiple lines of CHO cells and some are good at making some antibodies and not others. This group investigated some cell lines that were good and less good at making particular proteins to see what the difference is. I'm not entirely clear on why they went straight to phosphoproteomics, but US HUPO 2025 was amazing but my work backlog wasn't and my brain is still toasty from digging myself out.
Turns out, though, that they are really excited by the patterns of phosphoproteomic alterations. From a production standpoint I'm not sure if the idea is that they could leverage some cell types and selected conditions to force advantageous production conditions - or if the idea is better applied to selecting the right cell lines for product production based on these information. Either way - antibody based drugs aren't going anywhere and it's cool to see proteomics addressing riddles beyond host cell contamination!
No comments:
Post a Comment